Nuveen
RXRX icon

Nuveen’s Recursion Pharmaceuticals RXRX Stock Holding History

Nuveen’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.32M Buy
1,721,154
+556,551
+48% +$1.85M ﹤0.01% 1958
2026
Q1 		$3.58M Buy
1,164,603
+79,678
+7% +$308K ﹤0.01% 2034
2025
Q4 		$4.44M Sell
1,084,925
-191,511
-15% -$949K ﹤0.01% 1962
2025
Q3 		$6.23M Buy
1,276,436
+50,778
+4% +$267K ﹤0.01% 1803
2025
Q2 		$6.2M Sell
1,225,658
-686,962
-36% -$3.37M ﹤0.01% 1777
2025
Q1 		$10.1M Buy
1,912,620
+842,670
+79% +$6.14M ﹤0.01% 1549
2024
Q4 		$7.23M Sell
1,069,950
-53,835
-5% -$362K ﹤0.01% 1786
2024
Q3 		$7.41M Buy
1,123,785
+373,632
+50% +$2.68M ﹤0.01% 1790
2024
Q2 		$5.63M Sell
750,153
-46,749
-6% -$408K ﹤0.01% 1891
2024
Q1 		$7.95M Buy
796,902
+239,999
+43% +$2.67M ﹤0.01% 1738
2023
Q4 		$5.49M Sell
556,903
-430,436
-44% -$3.07M ﹤0.01% 1926
2023
Q3 		$7.55M Sell
987,339
-138,306
-12% -$1.38M ﹤0.01% 1639
2023
Q2 		$8.41M Buy
1,125,645
+100,060
+10% +$700K ﹤0.01% 1625
2023
Q1 		$6.84M Sell
1,025,585
-121,844
-11% -$967K ﹤0.01% 1712
2022
Q4 		$8.85M Buy
1,147,429
+300,292
+35% +$2.94M ﹤0.01% 1577
2022
Q3 		$9.01M Buy
847,137
+278,555
+49% +$2.82M ﹤0.01% 1542
2022
Q2 		$4.63M Buy
568,582
+129,122
+29% +$864K ﹤0.01% 1992
2022
Q1 		$2.91M Buy
439,460
+69,254
+19% +$736K ﹤0.01% 2338
2021
Q4 		$6.67M Buy
370,206
+278,323
+303% +$5.24M ﹤0.01% 1939
2021
Q3 		$2.46M Buy
91,883
+13,153
+17% +$373K ﹤0.01% 2580
2021
Q2 		$2.87M Buy
+78,730
New +$2.33M ﹤0.01% 2537

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nuveen's RXRX Position: Q2 2026 in Review

Nuveen increased its Recursion Pharmaceuticals (RXRX) stake by 48% in Q2 2026, buying an estimated $1.85M and bringing the position to 1,721,154 shares worth $6.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1958.

Nuveen first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $10.1M in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Nuveen held 1,721,154 shares of Recursion Pharmaceuticals worth $6.32M as of Q2 2026.
  • Nuveen bought 556,551 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.85M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1958 holding.
  • Nuveen first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Nuveen's Recursion Pharmaceuticals position peaked at $10.1M in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.